华东数控(002248) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥74,821,808.99, representing a 21.72% increase year-over-year[3] - Net profit attributable to shareholders decreased by 56.36% to ¥1,441,080.03 in Q3 2023[3] - The net profit after deducting non-recurring gains and losses fell by 89.93% to ¥144,902.34[3] - Total operating revenue for the current period reached ¥226,460,671.06, an increase of 14.69% compared to ¥197,464,606.30 in the previous period[22] - Net profit attributable to shareholders of the parent company was ¥9,736,964.90, a decrease of 13.93% from ¥11,298,385.11 in the previous period[22] - The company reported a total profit of ¥9,605,476.18, down from ¥11,086,707.49 in the previous period[22] - Basic and diluted earnings per share decreased to ¥0.03 from ¥0.04 in the previous period[22] Cash Flow and Operating Activities - Cash flow from operating activities increased significantly by 298.29% to ¥30,945,736.42 year-to-date[3] - Operating cash flow net amount improved to ¥30,945,736.42, compared to a negative cash flow of ¥15,606,057.47 in the previous period[25] - Cash and cash equivalents at the end of the period totaled ¥40,955,254.77, up from ¥19,144,758.55 in the previous period[25] - The company received cash related to investment activities amounting to ¥37,700,000.00, compared to ¥23,000,000.00 in the previous period[25] Assets and Liabilities - Total assets at the end of Q3 2023 were ¥543,332,004.36, a decrease of 3.10% from the previous year[3] - The company's total assets as of September 30, 2023, amount to ¥543,332,004.36, a decrease from ¥560,740,396.04 at the beginning of the year[19] - Total current assets decreased from ¥440,493,573.77 to ¥425,377,752.43 during the same period[17] - Total liabilities decreased from ¥484,417,930.60 to ¥456,762,036.24[19] - The company's total equity as of September 30, 2023, is ¥86,569,968.12, up from ¥76,322,465.44 at the beginning of the year[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 76,558[11] - The largest shareholder, Weihai Weigao International Medical, holds 17.50% of shares, totaling 53,825,800 shares[11] Expenses - Financial expenses rose by 55.77% to ¥4,641,519.81 due to increased foreign exchange losses[8] - Research and development expenses were ¥7,358,731.81, slightly up from ¥7,202,158.32 in the previous period[22] - Financial expenses increased to ¥4,641,519.81, compared to ¥2,979,806.81 in the previous period, with interest expenses at ¥5,046,166.69[22] Inventory and Receivables - The company experienced a 150.88% increase in accounts receivable, reaching ¥24,565,666.70 at the end of the reporting period[9] - The accounts receivable increased significantly from ¥9,791,710.60 to ¥24,565,666.70[17] - The company's inventory decreased from ¥276,668,433.72 to ¥250,493,649.87[17] Other Information - The company reported a net loss of ¥1,028,210,594.05 in retained earnings as of September 30, 2023[19] - The weighted average return on equity was 1.67%, down by 2.79% compared to the previous year[3] - The company has not undergone an audit for the third quarter report[13] - The company reported a 324.63% increase in taxes and surcharges to ¥1,501,334.86 year-to-date[8] - Total operating costs increased to ¥216,230,571.23, up 15.98% from ¥186,403,184.96 in the previous period[22]